Articles From: Allegiant Reports August 2014 Traffic to Allergan sues Valeant, alleging insider trading


http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=11G021150-001&sourceType=1 http://www.marketwire.com/library/MwGo/2014/9/4/11G021150/convertedPNGlogo-806567857.jpg LAS VEGAS, NV--(Marketwired - September 04, 2014) - Allegiant Travel Company (NASDAQ: ALGT) today reported preliminary passenger traffic results for August 2014.
Sign-up for Allegiant Reports August 2014 Traffic investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=11G019616-001&sourceType=1 http://www.marketwire.com/library/MwGo/2014/8/5/11G019616/convertedPNGlogo-896210768.jpg LAS VEGAS, NV--(Marketwired - August 05, 2014) - Allegiant Travel Company (NASDAQ: ALGT) today reported preliminary passenger traffic results for July 2014.
Sign-up for Allegiant Reports July 2014 Traffic investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=11G021571-001&sourceType=1 http://www.marketwire.com/library/MwGo/2014/9/11/11G021571/convertedPNGlogo-1346149828.jpg LAS VEGAS, NV--(Marketwired - September 11, 2014) - Allegiant (NASDAQ: ALGT) today announced the Company has purchased 200,000 shares of Allegiant company stock from CEO Maury Gallagher as part of the Company's stock repurchase program.
Sign-up for Allegiant Travel Company Announces the Repurchase of Shares of Allegiant Stock From Chairman and CEO Maury Gallagher investment picks
Allegion plc (NYSE: ALLE), a leading global provider of security products and solutions, is pleased to announce the completion of the sale of its United Kingdom (UK) door businesses to an affiliate of Alcyon Financial Limited, a financial investment firm.
Sign-up for Allegion Completes Sale of UK Doors & Service Businesses investment picks
Allegion plc (NYSE: ALLE), a leading global provider of security products and solutions, announced that its board of directors has declared a quarterly dividend of $0.08 cents per ordinary share of the company.
Sign-up for Allegion Declares Quarterly Dividend investment picks
Allegion plc (NYSE: ALLE) is highlighting its innovation pipeline, advancements in technology development, and additions to the company’s safety and security product portfolio.
Sign-up for Allegion Highlights Successes, New Products Launched Since Becoming Standalone Company investment picks
Allegion plc (NYSE: ALLE), a leading global provider of security products and solutions, today reported second quarter 2014 net revenues of $531.5 million, up 0.5 percent compared to the prior year, and net earnings of $51.6 million, or $0.53 per share from continuing operations.
Sign-up for Allegion Reports Second Quarter 2014 Financial Results; Updates Full-Year 2014 EPS Outlook investment picks
Allegion plc (NYSE: ALLE), a leading global provider of security products and solutions, today announced the signing of a definitive agreement to sell its United Kingdom (UK) Door businesses to an affiliate of Alcyon Financial Limited, a financial investment firm.
Sign-up for Allegion to Divest UK Doors & Service Businesses: Aims to Improve Focus in the Region investment picks
Allegion plc (NYSE: ALLE), a leading global provider of security products and solutions, is hosting two events to showcase the company’s recent innovations in its electronic security portfolio.
Sign-up for Allegion to Host Press Conference, School Security Seminar, at ASIS International 2014 investment picks
Allergan Inc. (NYSE: AGN) (“Allergan”) and TARIS Holdings LLC today announced that Allergan has closed a transaction to acquire worldwide rights to TARIS Biomedical’s ® (“TARIS”) lead program, LiRIS ® , which is currently in Phase 2 trials for the treatment of interstitial cystitis / bladder pain syndrome (IC/BPS). Allergan paid $67.5 million in cash upfront, subject to certain adjustments and holdbacks.
Sign-up for Allergan Acquires LiRIS® Program from TARIS Biomedical® investment picks
Allergan, Inc. (NYSE: AGN) announced today that the European Commission has extended the Marketing Authorization for OZURDEX ® (dexamethasone 700 mcg intravitreal implant in applicator) to treat adult patients with visual impairment due to diabetic macular edema (DME) who are pseudophakic (have an artificial lens implant), or who are considered insufficiently responsive to, or unsuitable for non-corticosteroids therapy.
Sign-up for Allergan Announces OZURDEX® (dexamethasone 700 mcg intravitreal implant in applicator) Now Approved in the European Union for the Treatment of Diabetic Macular Edema investment picks
Allergan, Inc. (NYSE: AGN) announced today that the European Union’s Committee for Medicinal Products for Human Use (CHMP) has recommended extending the Marketing Authorization for OZURDEX ® (dexamethasone 700 mcg intravitreal implant in applicator) to treat adult patients with vision loss due to diabetic macular edema (DME) who are pseudophakic (have an artificial lens implant), or who are considered insufficiently responsive to, or unsuitable for non-corticosteroid therapy.
Sign-up for Allergan Announces OZURDEX® (dexamethasone 700 mcg intravitreal implant in applicator) Receives European Positive Opinion for the Treatment of Diabetic Macular Edema investment picks
Allergan, Inc. (NYSE: AGN) invites you to listen to David Pyott, Chairman of the Board and Chief Executive Officer, and Jeff Edwards, Executive Vice President, Finance and Business Development, Chief Financial Officer, discuss the Company's second quarter 2014 results on Monday, July 21, 2014 beginning promptly at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time) before answering questions.
Sign-up for Allergan Announces Quarterly Conference Call investment picks
Allergan, Inc. (NYSE: AGN) (“Allergan” or the “Company”) today announced updates on three of the Company’s key R&D pipeline programs, including abicipar pegol (Anti-VEGF DARPin ® ), bimatoprost sustained-release implant for glaucoma and SEMPRANA™ (dihydroergotamine) inhalation aerosol (formerly referred to as LEVADEX ® ). In addition, Allergan announced that it has received approval from the U.S. Food and Drug Administration (FDA) for OZURDEX ® (dexamethasone intravitreal implant) 0.7 mg as a treatment option for diabetic macular edema (DME) in adult patients who have an artificial lens implant (pseudophakic) or who are scheduled for cataract surgery (phakic). “Allergan has a long track record of delivering stockholder value by efficiently investing in R&D to provide important new treatment options to address unmet patient needs,” said David E.I.
Sign-up for Allergan Announces R&D Pipeline Update and U.S. FDA Approval; Company to Host Conference Call Today, Monday, June 30th at 10:30 AM ET investment picks
NEW YORK (MarketWatch) -- Allergan Inc. shares (AGN) rose almost 2% in premarket trade Monday, after the Botox maker reported better-than-expected second-quarter profit and sales and said it is cutting 1,500 jobs, or 13% of its workforce, in a restructuring.
Sign-up for Allergan beats profit, sales estimates, to cut 1,500 jobs investment picks
Allergan, Inc. (NYSE: AGN) (“Allergan” or the “Company”) today issued the following statement regarding reports by Institutional Shareholder Services (“ISS”) and Glass Lewis on Pershing Square Capital Management, L.P’s (“Pershing Square”) solicitation to call a special meeting of Allergan’s stockholders (the “Special Meeting”). Goldman, Sachs & Co.
Sign-up for Allergan Comments on ISS and Glass Lewis Recommendations investment picks
Allergan, Inc. (NYSE: AGN) (“Allergan” or the “Company”) today provided the following comment in response to the definitive proxy solicitation filed by Pershing Square Capital Management, L.P. (“Pershing Square”) in connection with Pershing Square’s request to call a Special Meeting of Stockholders (the “Special Meeting”). At the Special Meeting, if called, Allergan stockholders would be asked to remove a majority of the Company’s existing directors in connection with Valeant Pharmaceuticals International, Inc.’s (“Valeant”) unsolicited exchange offer to acquire all outstanding common shares of Allergan for 0.83 shares of Valeant common stock and $72.00 in cash, or subject to proration, an amount of cash or a number of Valeant common shares with the implied value set forth in the exchange offer (the “Exchange Offer”). Goldman, Sachs & Co.
Sign-up for Allergan Comments on Pershing Square’s Definitive Proxy Solicitation investment picks
Allergan, Inc. (NYSE: AGN) (“Allergan” or the “Company”) today commented on Valeant Pharmaceuticals International, Inc.’s (“Valeant”) release of its second quarter 2014 earnings results.
Sign-up for Allergan Comments on Valeant’s Second Quarter 2014 Earnings Results investment picks
Allergan, Inc. (NYSE: AGN) (“Allergan” or the “Company”) today filed an answer in the United States District Court for the Central District of California responding to Valeant Pharmaceuticals International, Inc. (“Valeant”) and Pershing Square Capital Management, L.P.’s (“Pershing Square”) counterclaims regarding Allergan’s statements on the unsustainability of Valeant’s underlying business model.
Sign-up for Allergan Files Answer in Federal Court Responding to Valeant and Pershing Square’s Counterclaims investment picks
Allergan, Inc. (NYSE: AGN) (“Allergan” or the “Company”) today announced that it has filed an investor presentation with the Securities and Exchange Commission (“SEC”) and posted the presentation under the “Investors” section of the Company’s website describing “Further Thoughts on Potential Business Risks and Issues with Valeant Pharmaceuticals International, Inc. (“Valeant”).” This is a follow on presentation to Allergan’s May 27, 2014 presentation, “Certain Potential Business Risks and Issues with Valeant,” and June 10, 2014 presentation, “Allergan: A Specialist in the Biopharmaceutical & Medical Device Industries.” As previously announced, Allergan and important members of the investment community have raised serious concerns about Valeant’s anemic organic growth driven by unsustainable price increases, among other fundamental business model issues.
Sign-up for Allergan Files Investor Presentation investment picks
Allergan, Inc. (NYSE: AGN) (“Allergan” or the “Company”) today filed a lawsuit in the United States District Court for the Central District of California against Valeant Pharmaceuticals International, Inc. (“Valeant”), Pershing Square Capital Management, L.P. (“Pershing Square”) and its principal, William A.
Sign-up for Allergan Files Lawsuit in Federal Court against Valeant and Pershing Square for Violations of Federal Securities Laws investment picks
Allergan, Inc. (NYSE: AGN) (“Allergan” or the “Company”) today issued a statement regarding recent correspondence between Allergan and Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (“Valeant”) that was published by Valeant: Goldman, Sachs & Co.
Sign-up for Allergan Issues Statement Regarding Recent Valeant Correspondence investment picks
Allergan, Inc. (NYSE: AGN) (“Allergan” or the “Company”) today announced that Jim Hindman has been named Executive Vice President, Finance and Business Development, Chief Financial Officer, effective immediately.
Sign-up for Allergan Names Jim Hindman Chief Financial Officer investment picks
Allergan, Inc. (NYSE: AGN) (“Allergan” or the “Company”) today provided an update regarding the validity of the written requests from Allergan stockholders that were delivered by Pershing Square Capital Management, L.P. (“Pershing Square”) to request a Special Meeting of Stockholders (the “Special Meeting”). According to a review conducted by Allergan and its independent inspector, Pershing Square has delivered requests that comply as to form with Allergan's bylaws from stockholders owning more than 25% of Allergan’s shares, which does not include the additional requests from stockholders owning 2.8% of Allergan’s shares that were delivered on September 3, 2014.
Sign-up for Allergan Provides Update on Written Requests from Pershing Square Regarding Special Meeting of Stockholders investment picks
Allergan, Inc. (NYSE: AGN) (“Allergan” or the “Company”) today announced that the Company’s research and development pipeline has been recognized by the Galien Foundation, which has nominated three of Allergan’s products for the 2014 U.S. Prix Galien Awards.
Sign-up for Allergan R&D Innovations Recognized with Three Nominations for the 2014 U.S. Prix Galien Awards investment picks
Allergan, Inc. (NYSE: AGN) (“Allergan” or the “Company”) today announced that it received a request for additional information (a “Second Request”) under the Hart-Scott-Rodino Act from the U.S. Federal Trade Commission in connection with Valeant Pharmaceuticals International, Inc.’s unsolicited acquisition proposal of Allergan.
Sign-up for Allergan Receives Second Request from Federal Trade Commission Regarding Valeant’s Unsolicited Acquisition Proposal investment picks
Allergan, Inc. (NYSE: AGN) (“Allergan” or the “Company”) today confirmed that Pershing Square Capital Management, L.P. (“Pershing Square”) has delivered written requests from Allergan stockholders in connection with Pershing Square’s request to call a Special Meeting of Stockholders (the “Special Meeting”). At the Special Meeting, Allergan stockholders would be asked, among other things, to remove a majority of the Company’s existing directors in connection with Valeant Pharmaceuticals International, Inc.’s (“Valeant”) unsolicited exchange offer to acquire all outstanding common shares of Allergan for 0.83 shares of Valeant common stock and $72.00 in cash, or subject to proration, an amount of cash or a number of Valeant common shares with the implied value set forth in the exchange offer (the “Exchange Offer”). Allergan and an independent inspector will review the written requests submitted
Sign-up for Allergan Receives Written Requests from Pershing Square Regarding Special Meeting of Stockholders investment picks
Allergan, Inc. (NYSE: AGN) today announced operating results for the quarter ended June 30, 2014.
Sign-up for Allergan Reports Second Quarter 2014 Operating Results investment picks
By Russ Britt, MarketWatch Allergan Inc. turned up the heat on would-be suitor Valeant Pharmaceuticals International Inc. Monday with better-than-expected earnings and an improved outlook for 2014 and beyond, thanks to a cost-cutting program in which it will reduce its work force by 1,500 jobs.
Sign-up for Allergan results turn up the heat on Valeant investment picks
LOS ANGELES (MarketWatch) -- Allergan Inc. (AGN) filed a federal lawsuit Friday against would-be suitor Valeant Pharmaceuticals International Inc. (VRX), charging Valeant and activist investor William Ackman with violating insider trading laws.
Sign-up for Allergan sues Valeant, alleging insider trading investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Allegiant Reports August 2014 Traffic to Allergan sues Valeant, alleging insider trading
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices